Share on facebook Share on Twitter Share on Google Plus Share This
Back to Results

IDEAS


Title Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study: A Coverage with Evidence Development Longitudinal Cohort Study
Therapeutic Area Mild Cognitive Impairment
Principal Investigator Tinatin Chabrashvili, MD, PhD
Min Age 65 Years
Gender Both
Contact Sarah Gans
617 636-7606
More Information https://clinicaltrials.gov/ct2/show/NCT02420756

Overview

The purpose of this study is to examine how brain imaging with amyloid PET help guide your doctors in how to treat patients with mild cognitive impairment (MCI) or dementia and whether these changes in treatment lead to better medical outcomes. The hypothesis is that amyloid PET will decrease uncertainty and increase confidence in the underlying cause of cognitive impairment, that this will translate into earlier counseling and interventions in these domains, and that these interventions will lead to improved outcomes.

Study Details

Inclusion Criteria

  • Medicare as primary insurance
  • Diagnosis of mild cognitive impairment (MCI) or dementia
  • Cause of cognitive impairment is uncertain

Exclusion Criteria

  • Normal cognition or complaints not verified by cognitive testing
  • Amyloid status already known based on prior imaging
  • Hip/pelvic fracture within 12 months

Study Requirements

Participants will have an initial pre-PET clinic visit where medical history will be collected and the amyloid PET scan will be scheduled. They will then undergo the amyloid PET scan followed by a 90 day follow-up clinic visit to discuss the condition and management plans. Please allow for medical records and brain imaging to be collected for up to 3 years.

Number of research visits: 3

Length of participation: 3 years